WFDC2 and cancer: Compared with early-stage cancer, patients with advanced cancer had a worse prognosis, with a 12.768 times(3.668, 44.443) higher risk of death than early-stage cancer and 4.290 times(1.518, 12.129) higher risk of death in patients with abnormal HE4 than in normal patients.